Prevention of Damages of the Gastric and Duodenal Mucosa During Chemotherapy

Abstract

Abstract. The main goal of the study was to prevent the development of gastric and duodenal ulcers in patients with colorectal cancer receiving adjuvant therapy with 5-fluorouracil. Materials and methods. The study included 60 patients with a verified diagnosis of localized or locally advanced colon and rectosigmoid cancer after radical surgical treatment. The patients are divided into two groups. The first group included 28 people who were found to have Helicobacter pylori during fibro-gastroduodenoscopy and 13C-respiratory urease test. Patients underwent anti-Helicobacter and gastro-protective therapy before adjuvant chemotherapy with 5-fluorouracil according to the developed scheme. The second group included 32 people. Tests for infection with Helicobacter pylori in these patients were negative, they did not receive gastroprotective therapy. Research results. The study showed the effectiveness of prophylactic therapy administered to patients from the first group before the start of the adjuvant chemotherapy program, since ulcerative lesions of the mucous membranes of the stomach and duodenum in patients were detected less frequently, responded better to conservative therapy, and also did not cause a delay in the next course of drug treatment. including 5-fluorouracil. When preventive antiulcer treatment was administered, the chance of developing ulcer complications in patients decreased by 5.08 times. The most vulnerable in terms of mucosal damage were female pa-tients of elderly and senile age, complications developed even against the background of antiulcer treatment.